- Home
- SMBK vs KURA Comparison
SMBK vs KURA Comparison
Compare SMBK & KURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SMBK
- KURA
- Stock Information
- Founded
- SMBK N/A
- KURA 2014
- Country
- SMBK United States
- KURA United States
- Employees
- SMBK N/A
- KURA N/A
- Industry
- SMBK Major Banks
- KURA Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- SMBK Finance
- KURA Health Care
- Exchange
- SMBK Nasdaq
- KURA Nasdaq
- Market Cap
- SMBK 521.4M
- KURA 492.9M
- IPO Year
- SMBK N/A
- KURA N/A
- Fundamental
- Price
- SMBK $31.55
- KURA $6.30
- Analyst Decision
- SMBK Buy
- KURA Strong Buy
- Analyst Count
- SMBK 5
- KURA 12
- Target Price
- SMBK $34.40
- KURA $24.50
- AVG Volume (30 Days)
- SMBK 50.0K
- KURA 1.2M
- Earning Date
- SMBK 07-21-2025
- KURA 05-01-2025
- Dividend Yield
- SMBK 1.01%
- KURA N/A
- EPS Growth
- SMBK 44.84
- KURA N/A
- EPS
- SMBK 2.26
- KURA N/A
- Revenue
- SMBK $171,664,000.00
- KURA $67,991,000.00
- Revenue This Year
- SMBK $20.95
- KURA $171.90
- Revenue Next Year
- SMBK $9.48
- KURA $60.51
- P/E Ratio
- SMBK $13.96
- KURA N/A
- Revenue Growth
- SMBK 16.34
- KURA N/A
- 52 Week Low
- SMBK $21.40
- KURA $5.41
- 52 Week High
- SMBK $37.72
- KURA $23.48
- Technical
- Relative Strength Index (RSI)
- SMBK 53.26
- KURA 54.15
- Support Level
- SMBK $30.68
- KURA $5.56
- Resistance Level
- SMBK $32.27
- KURA $5.84
- Average True Range (ATR)
- SMBK 0.58
- KURA 0.36
- MACD
- SMBK -0.05
- KURA 0.02
- Stochastic Oscillator
- SMBK 43.87
- KURA 79.61
About SMBK SmartFinancial Inc.
SmartFinancial Inc operates as a bank holding company for SmartBank. It offers various banking and financial services to individuals and corporate customers. The principal business of the Bank consists of attracting deposits from the general public and investing those funds, together with funds generated from operations and from principal and interest payments on loans, mainly in commercial loans, commercial and residential real estate loans, consumer loans, and residential and commercial construction loans. The primary source of revenue is interest income from earning assets, namely loans and securities.
About KURA Kura Oncology Inc.
Kura Oncology Inc is a clinical-stage biopharmaceutical company, that engages in discovering and developing therapeutics for the treatment of solid tumors and blood cancers. It focuses on the development of small-molecule product candidates that target cell signaling pathways to drive the progression of various cancers. The company has a product candidate, Tipifarnib, which is a farnesyl transferase inhibitor, in both solid tumors and blood cancers. Geographically operation of the group is carried through the United States.